留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

UGT1A1基因多态性对药物代谢和临床作用影响的进展

张喆,  蔡卫民

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(6): 488-492
张喆, 蔡卫民. UGT1A1基因多态性对药物代谢和临床作用影响的进展[J]. 药学实践与服务, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
引用本文: 张喆, 蔡卫民. UGT1A1基因多态性对药物代谢和临床作用影响的进展[J]. 药学实践与服务, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu
ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
Citation: ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu

UGT1A1基因多态性对药物代谢和临床作用影响的进展

doi: 10.3969/j.issn.1006-0111.2018.06.003

  • 上海复旦大学药学院, 上海 201203

Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy

  • School of Pharmacy, Fudan University, Shanghai 201203, China

  • 摘要: UGT1A1基因是参与人体代谢循环的重要基因，随着药物基因组学的发展，发现其基因多态性与某些药物代谢水平相关，进而影响疾病的发生、发展及治疗等诸多方面。随着研究进展，UGT1A1的底物在不断扩展，包括胆红素、雌激素、伊立替康及其他一些药物已有研究。研究UGT1A1基因多态性对药物代谢情况的影响，在临床疾病的诊治、预后判断及药物不良反应等方面有重要的指导意义。
    Abstract: UGT1A1 is an important gene in the process of drug metabolism. With the development of pharmacogenomics,which have been found that the UGT1A1 gene polymorphisms is relevant to the level of metabolism, affect the occurrence,development and treatment of disease. As the study progressed, the substrates of UGT1A1 have constantly been extended, including bilirubin, estrogen, irinotecan and some other drugs with a number of studies. Research on the relationship between UGT1A1 gene polymorphisms and these substrates have showed that UGT1A1 gene polymorphisms play an important significance on the clinic diagnosis and treatment, prognostic judgments and drug side effects. The research progress of the role of UGT1A1 gene polymorphisms to drug metabolism and clinical effects were reviewed in this paper.
  • [1] 郭栋,庞良芳,周宏灏. UGT酶的遗传药理学研究进展[J]. 中国新药杂志,2011,20(13):1188-1193.
    [2] 李登,王潞. UGT1A1基因多态性与伊立替康致迟发性腹泻及治疗的研究进展[J]. 科技信息, 2014(3):271-272.
    [3] 韦小兰,骆子义,邬宇美,等. 利用多重实时荧光定量PCR技术检测新生儿高胆红素血症患者UGT1A1基因多态性研究[J]. 新发传染病电子杂志, 2017(1):18-21+39.
    [4] 田玉廷. UGT1A1基因多态性研究进展[J]. 实用癌症杂志, 2013, 28(3):324-326.
    [5] 侯慧轩. 亚洲人群晚期结直肠癌UGT1A1基因多态性与伊立替康相关毒性的meta分析[D]. 乌鲁木齐:新疆医科大学, 2016.
    [6] INNOCENTI F,VOKES EE,RATAIN MJ. Irinogenetics:what is the right star?[J]. J Clin Oncol, 2006, 24(15):2221-2224.
    [7] YANG Y,ZHOU M,HU M,et al. UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity:a meta-analysis[J]. Asia-Pacific J Clin Oncol, 2018, 14(5):e479-e489.
    [8] FUKUDA M,OKUMURA M,IWAKIRI T,et al. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer[J]. Thorac Cancer, 2018, 9(1):51-58.
    [9] MCLEOD HL,SARGENT DJ,MARSH S,et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer:results from North American gastrointestinal intergroup trial N9741[J]. J Clin Oncol, 2010, 28(20):3227-3233.
    [10] 衡雪源,车峰远,来向阳,等. 中国部分地区肿瘤患者UGT1A1*28和UGT1A1*6位点基因多态性分布的差异研究[J]. 2016, 19(30):3705-3710.
    [11] LI GY,DUAN JF,LI WJ,et al. DPYD*2A/*5A/*9A and UGT1A1*6/*28 polymorphisms in Chinese colorectal cancer patients[J]. J Cancer Res Ther, 2016, 12(2):782-786.
    [12] 叶茂芳. UGT1A1基因多态性与伊立替康毒性和疗效相关性的回顾性研究[D]. 济南:山东大学, 2017.
    [13] 栾家杰,刘俊,汪琳,等. 安徽地区汉族人群肿瘤患者UGT1A1*6基因多态性分布的差异性研究[J]. 中国药理学通报, 2018, 34(6):857-862.
    [14] NAKAMURA Y,SODA H,OKA M,et al. Randomized phase Ⅱ trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer:association of UGT1A1*6 and UGT1A1*27 with severe neutropenia[J]. J Thorac Oncol, 2011, 6(1):121-127.
    [15] RADOI VE,URSU RI,POENARU E,et al. Frequency of the UGT1A1*28 polymorphism in a Romanian Cohort of Gilbert syndrome individuals[J]. J Gastrointestin Liver Dis, 2017, 26(1):25-28.
    [16] MAZUR-KOMINEK K,ROMANOWSKI T,BIELAWSKI K,et al. Association between uridin diphosphate glucuronosylotransferase 1A1(UGT1A1) gene polymorphism and neonatal hyperbilirubinemia.[J]. Acta Biochim Pol, 2017,64(2):351-356.
    [17] KUO S,YANG S,YOU S,et al. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer[J]. Oncotarget, 2017, 8(13):20925-20938.
    [18] ADEGOKE OJ,SHU XO,GAO YT,et al. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1(UGT1A1) and risk of breast cancer[J]. Breast Cancer Res Treat, 2004, 85(3):239-245.
    [19] 田玉廷. UGT1A1基因多态性与乳腺癌发病风险的关系[D]. 石家庄:河北医科大学,2013.
    [20] DEMING SL,ZHENG W,XU WH,et al. UGT1A1 genetic polymorphisms, endogenous estrogen exposure, soy food intake, and endometrial cancer risk[J]. Cancer Epidemiol Biomark Prev, 2008, 17(3):563-570.
    [21] YOKOTA M,HIRASAWA A,MAKITA K,et al. Polymorphisms of estrogen metabolism-related genes ESR1, UGT2B17, and UGT1A1 are not associated with osteoporosis in surgically menopausal Japanese women.[J]. Menop Rev, 2015, 14(3):161-167.
    [22] 段舟萍. UGT1A1*6及*28基因多态性对伊立替康毒副反应及疗效影响的研究[D]. 南昌:南昌大学, 2015.
    [23] IYER L,DAS S,JANISCH L,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity[J]. Pharmacogenomics J, 2002, 2(1):43-47.
    [24] 张君孝,王晨亮,黄美近,等. UGT1A1基因多态性与转移性结直肠癌伊立替康化疗毒性及疗效的关系[J]. 中国病理生理杂志, 2012,28(5):823-828.
    [25] CHEN X,LIU L,GUO Z,et al. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer:a meta-analysis[J]. Cancer Chemother Pharmacol, 2017, 79(6):1109-1117.
    [26] TAKANO M,SUGIYAMA T. UGT1A1 polymorphisms in cancer:impact on irinotecan treatment[J]. Pharmgenom Pers Med, 2017, 10:61-68.
    [27] LU CY,HUANG CW,WU IC,et al. Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting[J]. Transl Oncol, 2015, 8(6):474-479.
    [28] TOFFOLI G,CECCHIN E,CORONA G,et al. The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2006, 24(19):3061-3068.
    [29] SCHULZ C,HEINEMANN V,SCHALHORN A,et al. UGT1A1 gene polymorphism:impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer[J]. World J Gastroenterol, 2009, 15(40):5058-5066.
    [30] XU CL,TANG XS,QU YL,et al. UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer[J]. Cancer Chemother Pharmacol, 2016, 78(1):119-130.
    [31] LUSIN TT,MRHAR A,TRONTELJ J. UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene[J]. Pharmazie, 2015, 70(2):94-96.
    [32] BINS S,LENTING A,EL BOUAZZAOUI S,et al. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity[J]. Pharmacogenomics, 2016, 17(14):1483-1490.
    [33] YAGURA H,WATANABE D,ASHIDA M,et al. Correlation between UGT1A1 polymorphisms and raltegravir plasma trough concentrations in Japanese HIV-1-infected patients[J]. J Infect Chemother, 2015, 21(10):713-717.
    [34] de OLIVEIRA ALMEIDA VC,RIBEIRO DD,GOMES KB,et al. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis:a prospective cohort study[J]. Mol Diagn Ther, 2014, 18(6):675-683.
    [35] IGARASHI R,INOUE T,FUJIYAMA N,et al. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma[J]. Med Oncol, 2018, 35(4):51.
    [36] CHEN P,ZHU KW,ZHANG DY,et al. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens[J]. J Transl Med, 2018, 16(1):197.
  • [1] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [2] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [3] 何静, 安晔, 张朝绅.  复方黑参滴丸与复方黑参丸药效学实验比较研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404009
    [4] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [5] 岳春华, 贲永光, 王海桥.  基于NLRP1炎症小体探讨百合知母汤抗抑郁的作用机制 . 药学实践与服务, 2024, 42(8): 325-333. doi: 10.12206/j.issn.2097-2024.202401033
    [6] 李想, 陆鸿远, 张明玉, 高欢, 姚东, 许子华.  米格列醇激活UCP1介导棕色脂肪对冷暴露小鼠损伤的研究 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404005
    [7] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [8] 杨嘉宁, 赵一颖, 肖伟.  七味脂肝方对非酒精性脂肪性肝炎动物模型的药效学评价 . 药学实践与服务, 2024, 42(9): 389-398. doi: 10.12206/j.issn.2097-2024.202404096
    [9] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [10] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [11] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [12] 陈怡君, 王卓, 何苗, 张宇, 田泾.  泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
    [13] 姚瑞阳, 于海征, 李耀盺, 张磊.  丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
    [14] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [15] 张元林, 宋凯, 孙蕊, 舒飞, 舒丽芯, 杨樟卫.  基于真实世界数据的药物利用研究综述 . 药学实践与服务, 2024, 42(6): 238-243. doi: 10.12206/j.issn.2097-2024.202312010
    [16] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [17] 夏哲炜, 曾垣烨, 朱海菲, 李育, 陈啸飞.  核磁共振磷谱法测定磷酸氢钙咀嚼片中药物含量 . 药学实践与服务, 2024, 42(9): 399-401, 406. doi: 10.12206/j.issn.2097-2024.202404063
    [18] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [19] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [20] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3423
  • HTML全文浏览量:  451
  • PDF下载量:  1464
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-07-17
  • 修回日期:  2018-10-09

UGT1A1基因多态性对药物代谢和临床作用影响的进展

doi: 10.3969/j.issn.1006-0111.2018.06.003
  • 上海复旦大学药学院, 上海 201203
  • 收稿日期: 2018-07-17
  • 修回日期: 2018-10-09

摘要: UGT1A1基因是参与人体代谢循环的重要基因，随着药物基因组学的发展，发现其基因多态性与某些药物代谢水平相关，进而影响疾病的发生、发展及治疗等诸多方面。随着研究进展，UGT1A1的底物在不断扩展，包括胆红素、雌激素、伊立替康及其他一些药物已有研究。研究UGT1A1基因多态性对药物代谢情况的影响，在临床疾病的诊治、预后判断及药物不良反应等方面有重要的指导意义。

English Abstract

张喆, 蔡卫民. UGT1A1基因多态性对药物代谢和临床作用影响的进展[J]. 药学实践与服务, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
引用本文: 张喆, 蔡卫民. UGT1A1基因多态性对药物代谢和临床作用影响的进展[J]. 药学实践与服务, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu
ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
Citation: ZHANG Zhe, CAI Weimin. Research progress on the effect of UGT1A1 gene polymorphisms on drug metabolism and clinical efficacy[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 488-492. doi: 10.3969/j.issn.1006-0111.2018.06.003
shu

    全文HTML

参考文献 (36)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计